Navigation Links
Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine
Date:9/15/2009

Expressionist modules Refiner Array and Analyst deliver expanded processing and reporting functionalities.

Basel, Switzerland and Lexington, MA (PRWEB), September 15, 2009 -- Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced the release of Genedata Expressionist® 5.3 with enhanced capabilities for transcriptomics-based biomarker discovery for applications in drug profiling and patient selection.

"Expressionist can analyze large amounts of data with highly sophisticated statistical features, not only to visualize your data but also to pre-process them, perform classical statistical analysis, and very high-end classification and prediction," said Dr. Sergio Baranzini, Associate Professor in the Department of Neurology at the University of California San Francisco. Baranzini's team is part of an academic research consortium studying the genetics of multiple sclerosis. "We tested the breadth of software possibilities and Genedata Expressionist goes beyond the capabilities of most software I've ever worked with," continued Baranzini. "Expressionist's intuitive nature eliminates the trial-and-error process that usually can't be avoided when working with analytical software."

Expressionist 5.3 expands the process capabilities of its Refiner Array module to support the next generation of microarrays, including Affymetrix Whole-Transcript and Exon arrays. In response to the growing importance of customized arrays, flexibility in pre-processing raw data has been increased by incorporating array type-specific layout information. Furthermore, data quality assessment functionality as well as access to biological information has been significantly enhanced. To support automated workflow-based SOPs for applications in personalized medicine, a completely new reporting engine has been developed. Processing performance has also been optimized to enable efficient analysis of large-scale microarray projects.

"The release of Expressionist 5.3 is another major step in supporting high-performance data processing and accurate data analysis of the large-scale microarray projects that are becoming standard in drug discovery and related life science applications," noted Dr. Othmar Pfannes, CEO of Genedata. Recent Expressionist releases have already augmented technology support in transcriptomics, proteomics and metabolomics as well as enabled high-end cross-omics data processing for mass spectrometry and transcriptomics data.

"Genedata is committed to supporting novel technologies and providing innovative solutions to meet the needs of our users and the demands of constantly evolving technologies," continued Dr. Pfannes. "As an independent company with a proven track record of delivering best-in-class services to customers around the world, we look forward to collaborating with our partners to improve the efficiency of drug discovery and development in the life sciences."

About Genedata
Genedata develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata's solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan. For more information, please visit www.genedata.com.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

###

Read the full story at http://www.prweb.com/releases/Genedata/Expressionist/prweb2878464.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities
2. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
3. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
4. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
5. Ingenuity Systems Joins Biomarkers Consortium
6. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
7. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
8. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project
11. Genetic Engineering & Biotechnology News reports on cancer biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):